Abacus Medicine Pharmaceuticals

Executive Summary

Abacus Medicine Pharmaceuticals is a UK-based, European-focused commercialisation partner for rare and specialty disease therapies. Founded in 2015, it offers end-to-end go-to-market solutions including market access, medical affairs, regulatory services, and supply chain management. By leveraging its physical presence and legal entities across key European markets, Abacus enables biotech and pharmaceutical innovators to accelerate patient access and launch products efficiently. The company acts as a strategic partner, reducing the complexity and cost of European market entry for its clients. Given the growing pipeline of rare disease therapies and the increasing need for local expertise in European markets, Abacus is well-positioned to capture a share of this outsourcing demand. Its asset-light model and recurring revenue from service contracts provide a stable financial base.

Upcoming Catalysts (preview)

• Q3 2026New partnership with a mid-sized biotech for EU commercialisation70% success
• Q4 2026Expansion into Nordic and Eastern European markets60% success
• Q1 2027Regulatory approval for a partner's product in a key EU country50% success